<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655118</url>
  </required_header>
  <id_info>
    <org_study_id>TL-895-201</org_study_id>
    <nct_id>NCT04655118</nct_id>
  </id_info>
  <brief_title>Study of TL-895 in Subjects With Myelofibrosis</brief_title>
  <official_title>A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Telios Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Telios Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates TL-895, a potent, orally-available and highly selective irreversible&#xD;
      tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must be&#xD;
      relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive&#xD;
      JAKi treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Objective, Part A: To determine the RP2D of TL-895 in each cohort.</measure>
    <time_frame>9 months</time_frame>
    <description>The safety review committee (SRC) will determine the RP2D for Cohorts 1, 2 and 3 based on safety and tolerability data obtained from each arm of that cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Objective, Part B: To determine the SVR rate of Cohorts 1, 2, and 3 at Week 24.</measure>
    <time_frame>Week 24</time_frame>
    <description>The proportion of subjects achieving ≥35% spleen volume reduction at Week 24 by MRI or CT scan (central review).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key Secondary Objective: Improvement in Total Symptom Score at Week 24.</measure>
    <time_frame>Week 24</time_frame>
    <description>The proportion of subjects achieving ≥50% reduction in Total Symptom Score at Week 24 by MFSAF v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key Secondary Objective: To determine the duration of response (DOR).</measure>
    <time_frame>44 months</time_frame>
    <description>Time from initial response to progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key Secondary Objective: To determine the progression-free survival (PFS).</measure>
    <time_frame>44 months</time_frame>
    <description>Time from the first dose to progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key Secondary Objective: To determine the duration overall response (OS).</measure>
    <time_frame>44 months</time_frame>
    <description>Time from the first dose to death of any cause.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Arm 1a, Relapsed/Refractory Myelofibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1b, Relapsed/Refractory Myelofibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2a, JAKi Intolerant Myelofibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2b, JAKi Intolerant Myelofibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3a, JAKi Ineligible Myelofibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3b, JAKi Ineligible Myelofibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1 Expansion, Relapsed/Refractory Myelofibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TL-895 administered orally at RP2D and schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 Expansion, JAKi Intolerant Myelofibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TL-895 administered orally at RP2D and schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 Expansion, JAKi Ineligible Myelofibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TL-895 administered orally at RP2D and schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TL-895</intervention_name>
    <description>TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.</description>
    <arm_group_label>Arm 1 Expansion, Relapsed/Refractory Myelofibrosis</arm_group_label>
    <arm_group_label>Arm 1a, Relapsed/Refractory Myelofibrosis</arm_group_label>
    <arm_group_label>Arm 1b, Relapsed/Refractory Myelofibrosis</arm_group_label>
    <arm_group_label>Arm 2 Expansion, JAKi Intolerant Myelofibrosis</arm_group_label>
    <arm_group_label>Arm 2a, JAKi Intolerant Myelofibrosis</arm_group_label>
    <arm_group_label>Arm 2b, JAKi Intolerant Myelofibrosis</arm_group_label>
    <arm_group_label>Arm 3 Expansion, JAKi Ineligible Myelofibrosis</arm_group_label>
    <arm_group_label>Arm 3a, JAKi Ineligible Myelofibrosis</arm_group_label>
    <arm_group_label>Arm 3b, JAKi Ineligible Myelofibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥18 years of age&#xD;
&#xD;
          -  Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating&#xD;
             physician according to the World Health Organization (WHO) criteria&#xD;
&#xD;
          -  Palpable spleen measuring ≥5 cm below the LLCM or spleen volume of ≥450 cm3 by MRI or&#xD;
             CT scan assessment&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2&#xD;
&#xD;
          -  Adequate hematologic, hepatic, and renal functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with any BCR-ABL, phosphoinositide 3-kinase (PI3K), mammalian target&#xD;
             of rapamycin (mTOR), bromodomain and extraterminal domain (BET) or spleen tyrosine&#xD;
             kinase (Syk) inhibitors&#xD;
&#xD;
          -  Cohorts 1 and 2 - Prior treatment with JAKi within 21 days of the Screening MRI/CT&#xD;
             scan. Subjects in Cohort 3 must not have received JAKi&#xD;
&#xD;
          -  Prior splenectomy or splenic irradiation within 24 weeks prior to first dose of study&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne Uyei, MD</last_name>
    <phone>650-353-6896</phone>
    <email>auyei@teliospharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherry Toney</last_name>
    <email>SToney@teliospharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute - Royal Oak</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute - Sterling Heights</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>East Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre South Brisbane</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern Oncology Specialists</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Sydney</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu De Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Georgi Stranski</name>
      <address>
        <city>Pleven</city>
        <zip>5809</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital &quot;St Ivan Rilski&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Specialized Hospital for Active Treatment of Hematological Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Duesseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Markhot Ferenc Oktatokorhaz es Rendelointezet</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmár-Bereg Megyei Önkormányzat Jósa András Oktatókórház Megyei-Városi Tüdőgondozó Intézete</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>S. Orsola-Malpighi Polyclinic</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Gaspare Rodolico</name>
      <address>
        <city>Catania</city>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano Bianchi Melacrino Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Klinika Hematologi</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii Collegium Medicum Uniwersytetu Jagiellonskiego</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - L'Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Salamanca University Hospital</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Quirónsalud Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

